19 January 2021 - Meta
Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
et al., Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)
Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52], p = 0.0002.A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) [1, 2, 3]. Reportedly, Unitaid had influence over the conclusions [4, 5]. See also [6].Note that one of the 18 studies in this analysis has since been withdrawn (Elgazzar).
|
risk of death, 75.0% lower, RR 0.25, p < 0.001.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Hill et al., 1/19/2021, preprint, 40 authors.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.